Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Ramosetron in Diarrhea Predominant Irritable Bowel Syndrome
NCT07574320Phase 4Not yet recruiting
- Start
- Apr 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in Irritable bowel syndrome with diarrhea (IBS-D) comparing Ramosetron 2.5 microgram with Placebo (2 arms). Primary endpoint: IBS Symptom Severity Score at 8 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
ramosetron
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT07574320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07574320.